Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission. Ferring Pharmaceuticals ...

WASHINGTON -- Once-daily budesonide in gastro-resistant capsule form (Budenofalk) showed promise as an oral treatment for lymphocytic colitis, a manufacturer-sponsored phase III study demonstrated. At ...

Agreement follows ex-US divestment of Entocort in July 2015 23 November 2015 - AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US ...

With Calliditas Therapeutics' drug formulation, designed to unlock a new use case for the common corticosteroid budesonide, under review in the E.U. and U.S., Stada has struck a deal to bring it to ...

The US Food and Drug Administration (FDA) announced accelerated approval for budesonide delayed release capsules (Tarpeyo) to reduce proteinuria in adults with primary immunoglobulin A (IgA) ...

Sufferers of Crohn’s disease won a new treatment that promises to decrease the intestinal inflammation that causes much of the disorder’s misery. The Food and Drug Administration approved Entocort EC, ...

* Has completed its agreement with Perrigo Company Plc for divestment of US rights to Entocort (budesonide) * Upon completion of agreement, Perrigo paid Astrazeneca $380 million to acquire rights to ...

Calliditas Therapeutics AB’s full approval from the U.S. FDA for Tarpeyo (budesonide) delayed release capsules in immunoglobulin A nephropathy (IgAN) revived speculation about competitor Travere ...

In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β 2-agonist may be an alternative to conventional treatment strategies. We conducted a 52-week, double-blind ...